Background: Genitourinary syndrome of menopause (GSM) is the new term for vulvovaginal atrophy (VVA). The condition is relevant in more than 50% of women, having an adverse impact on quality of life and sexual relationships. Objective: To assess the efficacy and safety of a new type of non-ablative laser, Solid State Vaginal Laser (SSVL), for vaginal tissue regeneration and rejuvenation. Method: Eighty participants with GSM symptoms were treated with a total of 4 treatments in about two months (every 15 -20 days) of a nonablative SSVL (LASEmaR 1500™-EUFOTON). A cumulative intensity of GSM symptoms using a 10-cm VAS (dryness and/or burning and/or dyspareunia), the vaginal health index (VHI), the Female Sexual Function Index (FSFI) were evaluated. Urinary Incontinence Short Form (ICIQ-UI SF) and vaginal bioptic samples were also collected. Results: Improvement following the SSVL was observed on VHIS, VVA symptoms and sexual female function. This finding was also ratified by the improvement of vaginal histological features. After the SSVL treatment, almost all patients (91%) affected by urinary incontinence obtained the complete remission of symptoms. Conclusion: The objective evaluation of VHIS, FSFI and ICIQ-UI SF scores and the histological results indicates a real favorable effect of SSVL on GSM and on urinary incontinence.

No abstract

Background: Vulvovaginal atrophy (VVA) is a condition afflicting more than 50% of women and nowadays has changed his name in Genitourinary syndrome of menopause (GSM) due to the multiple aspects involved having an adverse impact on quality of life. Many treatment are now available and laser represent a new powerful option. The aim of this work is assess the histological effect of a new type of non-ablative laser, Solid State Vaginal Laser (SSVL), on vaginal tissue in women treated for GSM. Method: Eighty participants with GSM symptoms were treated with a total of 4 treatments in a two months timeframe (every 15-20 day) of a non-ablative SSVL (LASEmaR 1500™-EUFOTON). Vaginal biopic samples were collected before the start of the first treatment and after 4 weeks from the last one and an analysis of histological characteristics was conducted. A cumulative intensity of GSM symptoms using a 10-cm VAS (dryness and/or burning and/or dyspareunia), the vaginal health index (VHI), the Female Sexual Function Index (FSFI) and Urinary Incontinence Short Form (ICIQ-UI SF) were also evaluated. Results: Improvement in vaginal histological parameters for atrophy was demonstrated following the SSVL treatment. Amelioration was observed in order of thickening of the derma surface, phenomenon of glycogenic acanthosis, increased number and highness of papillae in chorion and in term of reduction in the inflammatory tissue infiltrate. Was also observed on VHIS, VVA symptoms and sexual female function. Conclusion: The evaluation of histological results indicates a favorable effect of SSVL on vaginal atrophy in GSM in terms of epithelium restauration as well as on inflammatory infiltration of the tissue.